# Cilostazol for Prevention of Recurrent Stroke Trial

> **NCT07174414** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Stanford University** · enrollment: 2000 (estimated)

## Conditions studied

- Stroke Recurrence
- Myocardial Infarction
- Vascular Death
- Ischemic Stroke
- TIA (Transient Ischemic Attack)
- Stroke (CVA) or Transient Ischemic Attack
- Recurrent Stroke

## Interventions

- **DRUG:** Cilostazol 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07174414
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2031-07
- **Final completion:** 2031-07
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174414, "Cilostazol for Prevention of Recurrent Stroke Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07174414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*